| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P17 | country | United States of America | Q30 |
| | Canada | Q16 |
| P582 | end time | 2021-10-29 | |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 246 | |
| P4844 | research intervention | crizotinib | Q5186964 |
| P6153 | research site | Korea University | Q39997 |
| | Barcelona Province | Q81949 |
| | Zhejiang University | Q197543 |
| | Complutense University of Madrid | Q219694 |
| | Institut Gustave Roussy | Q266227 |
| | National Taiwan University Hospital | Q1418766 |
| | King Chulalongkorn Memorial Hospital | Q1588587 |
| | hôpital Foch | Q3145155 |
| | Seoul National University Hospital | Q4403855 |
| | Fudan University | Q495015 |
| | Jeonbuk National University | Q623851 |
| | Samsung Medical Center | Q624119 |
| | ??? | Q2945711 |
| | Hospital Universitario 12 de Octubre | Q5902531 |
| | Pamela Youde Nethersole Eastern Hospital | Q7129290 |
| | Queen Elizabeth II Health Sciences Centre - Victoria General | Q7270360 |
| | Queen Mary Hospital, Hong Kong | Q7270465 |
| | Shanghai Chest Hospital | Q10867899 |
| | Changhua Christian Hospital | Q11070014 |
| | Henan Cancer Hospital | Q11141679 |
| | Gachon University Gil Hospital | Q12582491 |
| | Songklanagarind Hospital | Q13026879 |
| | IASO General Hospital | Q21626582 |
| | Universitary Hospital Virgen Macarena | Q27892167 |
| | Tianjin Medical University Eye Hospital | Q30254108 |
| | Guangzhou Medical University Cancer Hospital | Q30254263 |
| | Beijing Chest Hospital | Q30279996 |
| | Santa Maria delle Croci Hospital | Q30280383 |
| | Centro di Riferimento Oncologico | Q30281668 |
| | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Q30282164 |
| P1813 | short name | ALTA-3 | |
| P580 | start time | 2019-04-30 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase 3 Randomized Open-label Study of Brigatinib (Alunbrig®) Versus Alectinib (Alecensa®) in Advanced Anaplastic Lymphoma Kinase-Positive Non Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori®) | |